Covid Inquiry: Mistake not to consider range of pandemics – David Cameron
David Cameron says “group think” meant government focused on flu pandemics, rather than other diseases.
Similar Posts
This Viral, Fruit-Headed Doll And Its Tiny Penis Is Everyone’s Emotional Support Crutch
Attendee Judy Gao, 20, said she met Saito in the dorms of NYU. Gao moved from Singapore to New York in 2021 and quickly experienced isolation in the new school, new city, and new country. She said handling her fears of COVID and rampant Asian hate crimes was overwhelming. “The worst was I moved to…
Hearing aid use could help people extend their lives, USC study finds
Wearing hearing aids could increase life span, a new study has found. Research by the Keck School of Medicine at the University of Southern California found that people who wear hearing aids regularly had a 24% lower risk of mortality. The study, published in The Lancet Healthy Longevity earlier this month, evaluated the history of…
“WaterTok” Has Quietly Become One Of The Most Polarizing Food Trends So Far In 2023 — Here’s Why
Water nausea, as it turns out, is actually a lesser-understood phenomenon, so I spoke with Dr. Supriya Rao — who is quadruple board-certified in internal medicine, gastroenterology, obesity medicine, and lifestyle medicine — to further explain these experiences. As Rao puts it, there are several reasons why one could experience nausea after drinking water, and…
Prescription drugs sold online without robust checks
More than 1,600 pills were bought by the BBC by entering false information online without challenge.
Asia’s year in review: Who had it good — and who had it bad — in 2023
Curtis S. Chin, a former U.S. ambassador to the Asian Development Bank, is managing director of advisory firm RiverPeak Group. Jose B. Collazo is an analyst focusing on the Indo-Pacific region. Follow them on X at @CurtisSChin and @JoseBCollazo. As 2023 comes to a close, we take a look at the year that was in…
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers’ drug pipeline after…
